KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $301000.0.

  • TherapeuticsMD's Other Accumulated Expenses changed N/A to $301000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $301000.0, marking a year-over-year change of. This contributed to the annual value of $88000.0 for FY2024, which is 7848.41% down from last year.
  • Per TherapeuticsMD's latest filing, its Other Accumulated Expenses stood at $301000.0 for Q3 2025.
  • TherapeuticsMD's Other Accumulated Expenses' 5-year high stood at $59.2 million during Q2 2022, with a 5-year trough of $88000.0 in Q4 2024.
  • Its 5-year average for Other Accumulated Expenses is $16.2 million, with a median of $11.5 million in 2023.
  • In the last 5 years, TherapeuticsMD's Other Accumulated Expenses skyrocketed by 58085.76% in 2021 and then tumbled by 9782.98% in 2023.
  • TherapeuticsMD's Other Accumulated Expenses (Quarter) stood at $13.3 million in 2021, then soared by 41.3% to $18.8 million in 2022, then tumbled by 97.83% to $409000.0 in 2023, then plummeted by 78.48% to $88000.0 in 2024, then surged by 242.05% to $301000.0 in 2025.
  • Its Other Accumulated Expenses stands at $301000.0 for Q3 2025, versus $202000.0 for Q2 2025 and $249000.0 for Q1 2025.